Table 4 Dose reductions and discontinuations
From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Characteristic | PTCL (N = 131) | CTCL (N = 102) |
|---|---|---|
Dose reduction due to adverse events, n (%) | 14 (11) | 14 (14) |
Dose interruptions due to adverse events, n (%) | 61 (47) | 35 (34) |
Discontinuation, n (%) | Â | Â |
 Progressive disease | 78 (60) | 22 (22) |
 Adverse event | 22 (17) | 24 (24) |
 Adverse event related to romidepsin treatment | 11 (8) | 17 (17) |
 Othera | 7 (5) | 26 (26) |